| D007052 |
Ibuprofen |
A non-steroidal anti-inflammatory agent with analgesic, antipyretic, and anti-inflammatory properties |
Advil,Benzeneacetic Acid, alpha-methyl-4-(2-methylpropyl)- trimethylsilyl ester,Brufen,Ibumetin,Ibuprofen, (+-)-Isomer,Ibuprofen, (R)-Isomer,Ibuprofen, (S)-Isomer,Ibuprofen, Aluminum Salt,Ibuprofen, Calcium Salt,Ibuprofen, Copper (2+) Salt,Ibuprofen, Magnesium Salt,Ibuprofen, Potassium Salt,Ibuprofen, Sodium Salt,Ibuprofen, Zinc Salt,Ibuprofen-Zinc,Motrin,Nuprin,Rufen,Salprofen,Trauma-Dolgit Gel,alpha-Methyl-4-(2-methylpropyl)benzeneacetic Acid,Ibuprofen Zinc,Trauma Dolgit Gel |
|
| D008297 |
Male |
|
Males |
|
| D008528 |
Mefenamic Acid |
A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase. |
Apo-Mefenamic,Contraflam,Coslan,Dysman,Mefac,Mefacit,Mefenaminic Acid,Mefic,Nu-Mefenamic,PMS-Mefenamic Acid,Parkemed,Pinalgesic,Ponalar,Ponalgic,Ponmel,Ponstan,Ponstan Forte,Ponstel,Ponsyl,Pontal,Acid, Mefenamic,Apo Mefenamic,Nu Mefenamic,PMS Mefenamic Acid |
|
| D010666 |
Phenylpropionates |
Derivatives of 3-phenylpropionic acid, including its salts and esters. |
|
|
| D002986 |
Clinical Trials as Topic |
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. |
Clinical Trial as Topic |
|
| D005260 |
Female |
|
Females |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D001172 |
Arthritis, Rheumatoid |
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. |
Rheumatoid Arthritis |
|